Muscular Dystrophy Association Conference 2023 (MDA)

Back

ACHIEVE Trial, a Randomized, Placebo-Controlled, Multiple Ascending Dose Study of DYNE-101 in Individuals With Myotonic Dystrophy Type 1 (DM1) (poster)

View

FORCE™ Platform Achieves Robust Exon Skipping, Restores Dystrophin at the Sarcolemma and Halts Progression of Fibrosis in the Severe D2-mdx Model of DMD (poster)

View

DELIVER, a Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study of DYNE-251 in Boys With DMD Amenable to Exon 51 Skipping (poster)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.